Protein-based therapy shows promise against resistant leukemia

The efficacy and safety of the new fusion protein has been demonstrated in mouse models of aggressive human leukemia using leukemia cells taken directly from patients with ALL. Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *